JP2017519727A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017519727A5 JP2017519727A5 JP2016566962A JP2016566962A JP2017519727A5 JP 2017519727 A5 JP2017519727 A5 JP 2017519727A5 JP 2016566962 A JP2016566962 A JP 2016566962A JP 2016566962 A JP2016566962 A JP 2016566962A JP 2017519727 A5 JP2017519727 A5 JP 2017519727A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- thieno
- triazolo
- chlorophenyl
- hydroxyphenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 16
- 229940124597 therapeutic agent Drugs 0.000 claims 16
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 9
- 239000007962 solid dispersion Substances 0.000 claims 6
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 4
- GNMUEVRJHCWKTO-FQEVSTJZSA-N 6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6s)- Chemical compound C([C@@H]1N=C(C2=C(N3C(C)=NN=C31)SC(=C2C)C)C=1C=CC(Cl)=CC=1)C(=O)NC1=CC=C(O)C=C1 GNMUEVRJHCWKTO-FQEVSTJZSA-N 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- YBPAYPRLUDCSEY-UHFFFAOYSA-N 2-(4-hydroxyphenyl)acetamide Chemical compound NC(=O)CC1=CC=C(O)C=C1 YBPAYPRLUDCSEY-UHFFFAOYSA-N 0.000 claims 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 2
- 229940121849 Mitotic inhibitor Drugs 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 229960005167 everolimus Drugs 0.000 claims 2
- 229940124302 mTOR inhibitor Drugs 0.000 claims 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 claims 1
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 230000009477 glass transition Effects 0.000 claims 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims 1
- 230000000394 mitotic effect Effects 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- 229960000235 temsirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461990457P | 2014-05-08 | 2014-05-08 | |
| US61/990,457 | 2014-05-08 | ||
| US201462012048P | 2014-06-13 | 2014-06-13 | |
| US62/012,048 | 2014-06-13 | ||
| US201462080751P | 2014-11-17 | 2014-11-17 | |
| US62/080,751 | 2014-11-17 | ||
| US201462086400P | 2014-12-02 | 2014-12-02 | |
| US62/086,400 | 2014-12-02 | ||
| US201562150044P | 2015-04-20 | 2015-04-20 | |
| US62/150,044 | 2015-04-20 | ||
| PCT/EP2015/060200 WO2015169951A1 (en) | 2014-05-08 | 2015-05-08 | Method of treating triple-negative breast cancer using thienotriazolodiazepine compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017519727A JP2017519727A (ja) | 2017-07-20 |
| JP2017519727A5 true JP2017519727A5 (https=) | 2018-06-14 |
Family
ID=53191652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016566962A Pending JP2017519727A (ja) | 2014-05-08 | 2015-05-08 | チエノトリアゾロジアゼピン化合物を用いる三種陰性乳癌の治療方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9968619B2 (https=) |
| EP (1) | EP3139959A1 (https=) |
| JP (1) | JP2017519727A (https=) |
| KR (1) | KR20170002610A (https=) |
| CN (1) | CN106852120A (https=) |
| AU (1) | AU2015257658A1 (https=) |
| BR (1) | BR112016026046A8 (https=) |
| CA (1) | CA2947970A1 (https=) |
| MX (1) | MX2016014574A (https=) |
| RU (1) | RU2016147946A (https=) |
| WO (1) | WO2015169951A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201506924YA (en) | 2013-03-15 | 2015-09-29 | Incyte Corp | Tricyclic heterocycles as bet protein inhibitors |
| EP3019502B1 (en) | 2013-07-08 | 2017-05-17 | Incyte Holdings Corporation | Tricyclic heterocycles as bet protein inhibitors |
| WO2015081189A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
| WO2015095492A1 (en) | 2013-12-19 | 2015-06-25 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
| PL3134403T3 (pl) | 2014-04-23 | 2020-07-13 | Incyte Corporation | 1H-pirolo[2,3-c]pirydyn-7(6H)-ony i pirazolo[3,4-c]pirydyn-7(6H)-ony jako inhibitory białek BET |
| JP6599979B2 (ja) | 2014-09-15 | 2019-10-30 | インサイト・コーポレイション | Betタンパク質阻害剤として用いるための三環式複素環化合物 |
| WO2017075377A1 (en) | 2015-10-29 | 2017-05-04 | Incyte Corporation | Amorphous solid form of a bet protein inhibitor |
| CA3028689A1 (en) | 2016-06-20 | 2017-12-28 | Incyte Corporation | Crystalline solid forms of a bet inhibitor |
| EP4118431B1 (de) * | 2020-03-12 | 2026-05-06 | Heinrich-Heine-Universität Düsseldorf | Inhibition von fkbp1a zur therapie des triple-negativen mammakarzinoms |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| WO2022261204A1 (en) | 2021-06-08 | 2022-12-15 | The Regents Of The University Of California | Anticancer compounds |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE404178T1 (de) * | 1999-02-10 | 2008-08-15 | Pfizer Prod Inc | Vorrichtung mit matrixgesteuerter wirkstofffreisetzung |
| WO2001095912A1 (fr) | 2000-06-16 | 2001-12-20 | Mitsubishi Pharma Corporation | Compositions permettant de reguler la plage et/ou la vitesse de liberation du ph |
| KR101600634B1 (ko) * | 2007-12-28 | 2016-03-07 | 미쓰비시 타나베 파마 코퍼레이션 | 항암제 |
| PL2902030T3 (pl) | 2010-05-14 | 2017-07-31 | Dana-Farber Cancer Institute, Inc. | Związki tienotriazolodiazepinowe do leczenia nowotworu |
| WO2012075456A1 (en) | 2010-12-02 | 2012-06-07 | Constellation Pharmaceuticals | Bromodomain inhibitors and uses thereof |
| JP2014513062A (ja) * | 2011-03-10 | 2014-05-29 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 癌の処置における使用のためのatip3およびその生物学的に活性なフラグメント |
| AU2013283378B2 (en) | 2012-06-25 | 2017-07-13 | Oncoethix Gmbh | Method of treating lymphoma using thienotriazolodiazepine compounds |
| WO2014004854A1 (en) * | 2012-06-27 | 2014-01-03 | The Curators Of The University Of Missouri | Induction of estrogen receptor beta by cholesterol biosynthesis inhibitors and methods of treatment of cancer |
| JP2015531365A (ja) | 2012-09-28 | 2015-11-02 | オンコエシックス エスエー | チエノトリアゾロジアゼピン化合物を含む医薬製剤 |
| US10238649B2 (en) * | 2012-10-04 | 2019-03-26 | Ab Science | Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors |
| US9492460B2 (en) | 2013-02-27 | 2016-11-15 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
| WO2015018523A1 (en) | 2013-08-06 | 2015-02-12 | Oncoethix Sa | A novel bet-brd inhibitor for treatment of solid tumors |
-
2015
- 2015-05-08 AU AU2015257658A patent/AU2015257658A1/en not_active Abandoned
- 2015-05-08 RU RU2016147946A patent/RU2016147946A/ru not_active Application Discontinuation
- 2015-05-08 MX MX2016014574A patent/MX2016014574A/es unknown
- 2015-05-08 JP JP2016566962A patent/JP2017519727A/ja active Pending
- 2015-05-08 EP EP15723671.2A patent/EP3139959A1/en not_active Withdrawn
- 2015-05-08 WO PCT/EP2015/060200 patent/WO2015169951A1/en not_active Ceased
- 2015-05-08 US US15/308,525 patent/US9968619B2/en not_active Expired - Fee Related
- 2015-05-08 KR KR1020167034522A patent/KR20170002610A/ko not_active Withdrawn
- 2015-05-08 BR BR112016026046A patent/BR112016026046A8/pt not_active IP Right Cessation
- 2015-05-08 CA CA2947970A patent/CA2947970A1/en not_active Abandoned
- 2015-05-08 CN CN201580037334.9A patent/CN106852120A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017519727A5 (https=) | ||
| RU2016147946A (ru) | Способ лечения трижды негативного рака молочной железы с использованием тиенотриазолодиазепиновых соединений | |
| JP2017529332A5 (https=) | ||
| RU2017100921A (ru) | Способ лечения немелкоклеточного рака легких и/или мелкоклеточного рака легких с применением соединений тиенотриазолодиазепина | |
| CY1125110T1 (el) | Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4 | |
| JP2013510123A5 (https=) | ||
| JP2012136540A5 (https=) | ||
| RU2014124184A (ru) | Комбинация ингибитора фосфоинозитид-3-киназы и модулятора пути янус-киназы 2 - проводника сигнала и активатора транскрипции 5 | |
| JP2013510124A5 (https=) | ||
| JP2018501315A5 (https=) | ||
| JP2016529246A5 (https=) | ||
| JP2017514907A5 (https=) | ||
| JP2013529611A5 (https=) | ||
| JP2014518544A5 (https=) | ||
| RU2014105577A (ru) | Капсулированная лекарственная форма, содержащая монтелукаст и левоцетиризин | |
| JP2016516067A5 (https=) | ||
| MX377635B (es) | Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos | |
| JP2017517579A5 (https=) | ||
| JP2019512535A5 (https=) | ||
| JP2016523974A5 (https=) | ||
| UY37843A (es) | Inhibidores de mcl-1 macrocíclicos y métodos de uso | |
| JP2015504091A5 (https=) | ||
| JP2015504081A5 (https=) | ||
| RU2013150861A (ru) | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний | |
| CY1123346T1 (el) | Παραγωγα 5-[2-(πυριδιν-2-υλαμινο)-1,3-θειαζολ-5-υλ]-2,3-διυδρο-1η-ισοϊνδολ-1-ονης και χρηση τους ως διπλοι αναστολεις της 3-κινασης φωσφατιδυλοϊνοσιτολης δελτα & γαμμα |